PERCEPTIVE ADVISORS LLC 13D and 13G filings for Spyre Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:15 pm Sale |
2024-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
PERCEPTIVE ADVISORS LLC | 2,574,723 4.400% |
-297,824 (-10.37%) |
Filing |
| 2024-11-14 4:33 pm Purchase |
2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE |
PERCEPTIVE ADVISORS LLC | 2,872,547 5.700% |
265,868 (+10.20%) |
Filing |
| 2024-02-14 4:27 pm Unchanged |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
PERCEPTIVE ADVISORS LLC | 2,606,679 7.200% |
0 (Unchanged) |
Filing |
| 2023-12-13 3:50 pm Purchase |
2023-11-24 | 13G | Spyre Therapeutics, Inc. SYRE |
PERCEPTIVE ADVISORS LLC | 2,606,679 7.200% |
2,606,679 (New Position) |
Filing |